Mikhail Blagosklonny is a science professor, author, and researcher with a bias in Oncology. He is based at Roswell Park Cancer Institute, New York. He studied internal medicine at the First Pavlov State Medical University of St. Petersburg and a doctorate in experimental medicine and cardiology at the same university. He currently works at Roswell Park Cancer Institute located in New York as a teaching and research professor.
His Editorial Life
With over 170 research articles, book chapters, and outstanding reviews, Mikhail has earned his place among the most prolific scientific authors. He is the Editor-In-Chief of two scientific publications: the weekly online journal Oncotarget and Cell Cycle. Mikhail is also the co-founder of Aging, a peer-reviewed journal published on a monthly basis by Impact Journals. He is currently a co-editor and associate editor for several medical journals. View Mikhail’s profile on Google Scholar
His Commitment to the Fight against Cancer
Mikhail’s commitment to the fight against the life-threatening disease of cancer is undoubted. He has contributed immensely to the research of cancer biology and therapy. At Roswell Cancer Institute, he specializes in biological research, especially in molecular and cellular biology. He also has interests in mitosis, apoptosis, cell cycle, and anticancer therapeutics. He is also in the forefront in the anti-aging drug research, which is expected to prolong human life by reducing the aging rate. This life extension drug will eliminate the age-related diseases like cancer.
Upon completing his Ph.D., Mikhail Blagosklonny moved to New York for his post-doctoral research. In 2002, he was given a job by the New York Medical College to teach as an associate professor of medicine. He later quit his job at the university to join the Ordway Research Institute in Albany, New York. Mikhail served as the senior scientist at the Institute until 2009 when he was offered a chance at Roswell Park Cancer Institute where he is a professor of Oncology to date.
TOR Signaling Hypothesis
One of Mikhail’s most notable hypotheses is his recent TOR Signaling hypothesis. In the hypothesis, he argued that TOR Signaling can be used in the prevention of both aging and cancer. He further explained that the Rapamycin drug has a potential of solving many cancer-related problems. This innovative hypothesis has earned him a lot of praise for compassionately advocating for the drug. Read more about Mikhail at LinkedIn .